One companion. Different journeys.
GLP-1, peptides approved or not, hormones, mood. One record.
A care plan has to work in real life.
Meals, movement, sleep, work and stress shape the days between appointments. Every journey runs on the same three things: what you take, how your body responds and how you feel. Aiden keeps them together, day after day, so the hard parts never happen alone.
Beyond approved therapies. Nobody falls out of view.
We record every product with its FDA status. We never recommend one.
Where most journeys begin.
Dose days, side effects, appetite, food noise, weight, protein and water, and how you feel on each of those days.
Daily check-ins, hard days after an increase, eating enough when hunger is gone, food noise that comes back at night, and the questions you want to ask your clinician.
Adherence, side effects and how you are really doing, in your own words, with your consent.
For people who track peptides beside GLP-1, training and recovery, and for clinician-directed care.
Product, amount, unit and day for everything you take, next to training load, sleep and recovery, with its FDA status always visible.
How you feel, sleep and recover over weeks. Aiden never recommends peptides or amounts.
What was really taken, when, and what changed, with your consent.
For people who want to see how daily habits show up in their markers, with the same companion.
Sleep, heart and activity from your wearable, and lab results such as HbA1c and lipids.
Biomarker trends beside daily life and how you feel, with your consent.
For the journey on testosterone (TRT), through perimenopause and menopause.
Mood, energy, sleep, libido, symptoms, cycles and the lab results you upload, over months.
Noticing how you change, talking it through without shame and preparing what to bring to your clinician.
We never guess hormone levels from a wearable. Labs and your clinician decide.
Sometimes it is easier to talk without shame, to someone who will not judge you.
Mood, stress, food noise, cravings and drinking less. Patterns, small steps and reconnecting with the people around you. Coaching and self-help, never therapy.
Substance use is not shared by default, private reflection is never shareable, and your clinician sees only what you choose.
Mood, anxiety, stress and validated check-ins, shown as trends, never as a diagnosis.
988 and the Crisis Text Line right away, your clinician informed if you chose that.
Change is lonely. Loneliness turns into anxiety.
A new medication, a body that changes, a plateau after months of work.
Progress can include a difficult day that no chart explains.
Private by default.
Your reflection stays yours unless you share it.
Your data tells us what's changing. Aiden asks how you're feeling.
From a daily check-in to a clearer follow-up. Each part adds context, and with your consent your clinician reads the whole story too.
Doses, adherence, side effects.
Weight, sleep, recovery, labs.
Mood, food noise, doubts.
One data type at a time, with consent.
Before a hard day becomes a stop.
Medications change appetite, cravings and mood.
Changes in cravings, sleep, stress or routine.
Private check-ins and practical support for the moment you are in.
What happened, without judgment, for your next conversation.
Behavior connected with medications and physiology.
evviro does not recommend, prescribe or supply medications, peptides or research compounds. What you take is recorded for your safety and your clinician's awareness, always with its FDA status. evviro is not an emergency service and does not replace licensed care.
Hormones, TRT and menopause: how the change feels, in your own words.
Semaglutide and tirzepatide tracking, between visits.
Whether you take Wegovy, Ozempic, Zepbound or Mounjaro, we keep doses, side effects, weight and nutrition on one timeline you can share with your care team.
Semaglutide tracking (Wegovy, Ozempic)
Log the semaglutide doses your clinician prescribed, injection day and site, and how you feel afterward. Weight, appetite, nausea, sleep and energy sit on one timeline.
Tirzepatide side effects tracker (Zepbound, Mounjaro)
Record side effects such as nausea, constipation or fatigue as they happen, see how they change from week to week, and share a clear summary with your care team.
Wegovy progress tracker
Follow weight, waist, protein, hydration and activity over months, not only between appointments.
Zepbound weight loss tracking
Weight entries, body measurements and supported wearable data in one place, with notes on what changed in your routine.
GLP-1 protein intake
Smaller appetite makes protein harder.
A GLP-1 companion app
Aiden checks in daily by voice or text, remembers what you shared and helps you prepare questions for your clinician. Aiden never changes, skips or recommends a dose.
Peptide tracking with the FDA status always visible.
Track BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, GHK-Cu, sermorelin, tesamorelin and other peptides with the amount you report, how you feel and your lab results. Approved or not, the record is complete and the status is clear.
Peptide tracking
Product, reported amount, unit, date and time, with symptoms, sleep and recovery alongside.
Safety signals first
Warning signs such as chest pain, trouble breathing or severe abdominal pain lead straight to 911 or your care team.
Shared on your terms
Your clinician sees peptide entries only when you choose to share them.
Peptide and GLP-1 reference: FDA status at a glance
We record what you report taking, approved or not, and always show its FDA status next to it. We never recommend a peptide, a product or a dose; your clinician decides. FDA status as checked by our team in September 2026, with later FDA actions noted. Every substance in our catalog is explained on Learn.
| Substance | FDA status (United States) | What it is |
|---|---|---|
| Semaglutide | FDA approved, indication specific | GLP-1 receptor agonist; approved products cover type 2 diabetes, chronic weight management and selected cardiovascular-risk indications. |
| Tirzepatide | FDA approved, indication specific | Dual GIP/GLP-1 receptor agonist; approved products cover type 2 diabetes, chronic weight management and obesity-related obstructive sleep apnea. |
| Liraglutide | FDA approved, indication specific | Daily GLP-1 receptor agonist for type 2 diabetes or chronic weight management, depending on the product. |
| Tesamorelin | FDA approved for HIV lipodystrophy | Growth-hormone-releasing-factor analogue for reducing excess abdominal fat in adults with HIV lipodystrophy; not a general weight-loss drug. |
| Bremelanotide (PT-141) | FDA approved for acquired, generalized HSDD | Approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder; not approved for men or erectile dysfunction. Products sold as “PT-141” are not the approved medicine. |
| Elamipretide (SS-31) | FDA approved for Barth syndrome (2025) | Mitochondria-targeting peptide approved to improve muscle strength in patients with Barth syndrome. |
| Retatrutide | Phase 3 investigational, not FDA approved | GIP/GLP-1/glucagon triple receptor agonist being studied for obesity, diabetes and related conditions. “Research use” products are no lawful substitute. |
| Cagrilintide | Investigational, not FDA approved | Amylin analogue being studied for obesity and diabetes, alone and combined with semaglutide (CagriSema, under FDA review for weight management). |
| BPC-157 | Not FDA approved; reviewed by FDA PCAC in 2026 | Marketed for gut, tendon or wound healing. There is no FDA-approved BPC-157 product. |
| TB-500 | Not FDA approved; reviewed by FDA PCAC in 2026 | Marketed for wound or musculoskeletal healing. TB-500 products may not be chemically identical to full thymosin beta-4. |
| CJC-1295 | Not FDA approved | Long-acting GHRH analogue marketed to raise growth hormone and IGF-1; chemical versions differ. |
| Ipamorelin | Not FDA approved; FDA 503B category 2 (may present significant safety risks) | Growth-hormone secretagogue peptide marketed for recovery, sleep or body composition. |
| MOTS-c | Not FDA approved; reviewed by FDA PCAC in 2026 | Mitochondrial-derived peptide marketed for metabolism, exercise, obesity or longevity. |
| AOD-9604 | Not FDA approved | Growth-hormone fragment marketed for fat loss. |
| Semax | Not FDA approved; reviewed by FDA PCAC in 2026 | ACTH-derived peptide marketed for cognition, migraine or neuroprotection. |
| Selank | Not FDA approved | Peptide marketed for anxiety, cognition or stress. |
| GHK-Cu | Not FDA approved; FDA 503A category 1 for non-injectable routes only | Copper-binding tripeptide marketed for skin, hair or wound care. Category 1 means “under evaluation”, not approved, and does not cover injections. |
| KPV | Not FDA approved; reviewed by FDA PCAC in 2026 | Alpha-MSH-derived tripeptide marketed for inflammation, gut or skin conditions. |
| Epitalon | Not FDA approved; reviewed by FDA PCAC in 2026 | Tetrapeptide marketed for sleep, aging or “telomere” effects. |
| Kisspeptin-10 | Not FDA approved; FDA 503A category 2 (significant safety concerns) | Reproductive-neuroendocrine peptide marketed for fertility, testosterone or libido. |
| Sermorelin | No current FDA-approved product; historical products discontinued | GHRH analogue marketed by peptide clinics for growth hormone deficiency, sleep or anti-aging. |
| Thymosin alpha-1 | Not FDA approved in the United States | Immune-modulating peptide approved in some other countries and marketed for infection, cancer support or “immune optimization”. |
TRT and menopause symptom tracking.
Testosterone therapy, menopause and perimenopause change how you sleep, feel and recover. Daily check-ins and lab history make those changes visible.
TRT symptom tracking
Track energy, mood, sleep, libido and training alongside the testosterone therapy your clinician manages, and upload lab results to see them over time.
Testosterone therapy tracking
Log what you take as prescribed, when you take it and how you feel. Share a member-approved history with your clinician before the next lab review.
Menopause symptoms tracker
Hot flashes, sleep, mood, cycle changes and energy in one daily check-in, so patterns become visible and easier to talk about.
Perimenopause sleep tracking
Connect sleep from your wearable and compare it with symptoms you log, night by night.